Open Access

Anti‑inflammatory effects of bone marrow mesenchymal stem cells on mice with Alzheimer's disease

  • Authors:
    • Yan Wei
    • Zhaohong Xie
    • Jianzhong Bi
    • Zhengyu Zhu
  • View Affiliations

  • Published online on: October 12, 2018     https://doi.org/10.3892/etm.2018.6857
  • Pages: 5015-5020
  • Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Anti‑inflammatory effects of bone marrow mesen­chymal stem cells (BMSCs) on mice with Alzheimer's disease (AD) were investigated. Twenty amyloid precursor protein (APP)/presenilin‑1 (PS1) double transgenic mice were randomly divided into two groups: the AD control group and the stem cell treatment group. The normal control group consisted of 10 non‑transgenic mice. The stem cell treatment group was injected with BMSCs, and the two control groups were given the same volume of normal saline. The Morris water maze test was used to compare the memory function of mice, and the relative expression levels of β‑site APP cleaving enzyme 1 (BACE1) and α‑2‑macroglobulin (A2M) genes were detected by fluorescence quantitative polymerase chain reaction (qPCR). Amyloid β (Aβ)1‑42 content in brain tissues of mice and inflammatory cytokines, interleukin (IL)‑1, IL‑2, IL‑10, tumor necrosis factor‑α (TNF‑α), and interferon‑γ (IFN‑γ) were detected using enzyme‑linked immunosorbent assay (ELISA). Compared with that in the AD control group, the escape latency in the water maze in the stem cell treatment group was shortened, the time of crossing the ring for the first time was decreased, but the frequency of crossing the ring was increased (P<0.05). Aβ1‑42 content in the AD control group was higher than that in the stem cell treatment group and the normal control group (P<0.05). The relative expression level of BACE1 gene in the stem cell treatment group was lower than that in the AD control group (P<0.05), but that of A2M gene was increased (P<0.05). At 14 days after treatment, the contents of IL‑1, IL‑2, TNF‑α and IFN‑γ in blood in the stem cell treatment group were lower than those in the AD control group (P<0.05). Human BMSCs can ameliorate the symptoms of AD by decreasing the levels of inflammatory cytokines and regulating the expression of Aβ‑related genes.
View References

Related Articles

Journal Cover

December-2018
Volume 16 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wei Y, Xie Z, Bi J and Zhu Z: Anti‑inflammatory effects of bone marrow mesenchymal stem cells on mice with Alzheimer's disease. Exp Ther Med 16: 5015-5020, 2018
APA
Wei, Y., Xie, Z., Bi, J., & Zhu, Z. (2018). Anti‑inflammatory effects of bone marrow mesenchymal stem cells on mice with Alzheimer's disease. Experimental and Therapeutic Medicine, 16, 5015-5020. https://doi.org/10.3892/etm.2018.6857
MLA
Wei, Y., Xie, Z., Bi, J., Zhu, Z."Anti‑inflammatory effects of bone marrow mesenchymal stem cells on mice with Alzheimer's disease". Experimental and Therapeutic Medicine 16.6 (2018): 5015-5020.
Chicago
Wei, Y., Xie, Z., Bi, J., Zhu, Z."Anti‑inflammatory effects of bone marrow mesenchymal stem cells on mice with Alzheimer's disease". Experimental and Therapeutic Medicine 16, no. 6 (2018): 5015-5020. https://doi.org/10.3892/etm.2018.6857